DeCure.ai

AMR Lab · DeCure for X

DeCure for Infectious mononucleosis

DeCure's autonomous AMR AI scientist is researching a drug-repurposing hypothesis for infectious mononucleosis — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.

Disease module2 genesLead labAMR
All cures
AMRDOID:8568$DeCureAMR

The disease map

Disease moduleInfectious mononucleosis maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.

Research record

01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash

Current lead

No approved-drug candidate for infectious mononucleosis is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.

Molecular view

TNF receptor superfamily member 17 (TNFRSF17) — TNFRSF17 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.

Loading structure…
helix sheet 2-hydroxy-ethyldrag to rotate · scroll to zoom

RCSB Protein Data Bank · entry 4ZFO · 1.895 Å · ligand 2-[BIS-(2-HYDROXY-ETHYL)-AMINO]-2-HYDROXYMETHYL-PROPANE-1,3-DIOL (BTB). Experimental structure, not a prediction.

What the evidence adds up to

In a 1953 textbook, infectious mononucleosis is described as a disease for which no specific treatment is discussed; the volume is a review of the condition itself. A 1968 review states that infectious mononucleosis is rarely severe enough to cause serious trouble, but when it does it may produce grave, even fatal complications. The same review notes that physicians generally cannot prevent these complications, though they can treat some patients with steroids and support others with general measures. No controlled trial data, response rates, or survival figures are given in either source.

A 2016 paper reports follow-up of 88 children aged 8.5 months to 17 years treated for infectious mononucleosis at a single hospital in Kazan in 2015–2016. It considers clinical manifestations in relation to the aetiology of the disease and hospitalisation outcomes, and assesses main laboratory changes. No specific drug treatment is evaluated, and no numerical outcomes such as duration of illness or complication rates are reported in the abstract.

A 2001 editorial states that infectious mononucleosis is a benign disease of healthy young people, and that patients and relatives expect a speedy and complete recovery. It explores unexpected diagnostic and management problems but does not report any trial of a specific drug or any quantitative outcome data. No evidence for any drug’s efficacy in treating infectious mononucleosis is provided across these abstracts.

What is missing is any randomised controlled trial testing a drug against placebo or standard care in infectious mononucleosis, with clearly defined endpoints such as time to symptom resolution, reduction in complication rates, or quality-of-life measures. No abstract provides data on patient stratification by age, severity, or viral load, nor any funding for such a trial.

Evidence

Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.

Annals of Internal Medicine · 1963 · 28 citations

Treatment of Infectious Mononucleosis

AbstractArticle1 February 1963Treatment of Infectious MononucleosisHAROLD R. SCHUMACHER, WILLIAM A. JACOBSON, CARL R. BEMILLER, M.D.HAROLD R. SCHUMACHER, WILLIAM A. JACOBSON, CARL R. BEMILLER, M.D.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-58-2-217 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThe treatment of infectious mononucleosis has been associated with the use of a broad array of drugs. The medications utilized largely paralleled or closely followed the eras in which great strides were made in control and cure of other diseases. Agents such as arsenicals and emetine (1) were tried and found to be of no benefit. Some of the earlier trials of antibiotics appeared to be beneficial (2-5), but other workers (6-9) have concluded that these drugs were ineffective. Steroids have been effective (10-12), and have resulted in marked relief of signs and symptoms in severely ill patients in relatively...References1. BERNSTEIN A: Infectious mononucleosis. Medicine 19: 85, 1940. CrossrefGoogle Scholar2. BURNETTMILNE JBJ: Aureomycin in treatment of infectious mononucleosis. New Engl. J. Med. 245: 495, 1951. CrossrefMedlineGoogle Scholar3. CARTERSYDNSTRICKER CHVP: Aureomycin in treatment of infectious mononucleosis. Amer. J. Med. 10: 309, 1951. CrossrefMedlineGoogle Scholar4. GRUSKIN BJ: Aureomycin in acute infectious mononucleosis. Ann. Intern. Med. 31: 678, 1949. LinkGoogle Scholar5. KANE P: Glandular fever and chloramphenicol. Brit. Med. J. 1: 1303, 1951. CrossrefMedlineGoogle Scholar6. MCGREEVEY JE: Infectious mononucleosis: report and discussion of a severe case with hepatitis and jaundice. Rocky Mountain Med. J. 47: 269, 1950. Google Scholar7. ROSEKNEELAND HMY: Aureomycin in treatment of infectious mononucleosis. Amer. J. Med. 7: 532, 1949. CrossrefMedlineGoogle Scholar8. SCHULTZHALL ALWH: Clinical observations in 100 cases of infectious mononucleosis and results of treatment with penicillin and aureomycin. Ann. Intern. Med. 36: 1498, 1952. LinkGoogle Scholar9. SEIFERTCHANDLERVANWINKLE MHVLW: Aureomycin in infectious mononucleosis. JAMA 142: 1133, 1950. CrossrefGoogle Scholar10. DORANWEISBERGER JKAS: The use of ACTH in infectious mononucleosis. Ann. Intern. Med. 38: 1058, 1953. LinkGoogle Scholar11. CREDITORMCCURDY MCHW: Severe infectious mononucleosis treated with prednisolone. Ann. Intern. Med. 50: 218, 1959. LinkGoogle Scholar12. RELKIN R: The use of steroids in infectious mononucleosis. New York J. Med. 60: 3876, 1960. MedlineGoogle Scholar13. GOTHBERG LA: Severe infectious mononucleosis treated with chloroquine phosphate. JAMA 173: 53, 1960. CrossrefMedlineGoogle Scholar14. PFEIFFER E: Drusenfieber. Jahrb. Kinderh. 29: 257, 1889. Google Scholar15. GOODING SE: On glandular fever or infective mononucleosis. Practitioner 127: 468, 1931. Google Scholar16. SMITHSHAW KSTH: Intravenous arsenic in treatment of anginous forms of glandular fever. Brit. Med. J. 1: 581, 1945. CrossrefMedlineGoogle Scholar17. SALTZMAN M: Therapeutic effect of bismuth in infectious mononucleosis. A preliminary statement with report of two cases. Laryngoscope 52: 697, 1942. CrossrefGoogle Scholar18. CREAGH EP: A case of infective mononucleosis (glandular fever). Brit. Med. J. 1: 185, 1933. Google Scholar19. LASSENTHOMSEN HCS: Treatment of infectious mononucleosis with specific convalescent serum. Acta Med. Scand. 104: 498, 1940. CrossrefGoogle Scholar20. TIDY HL Discussion on glandular fever. Proc. Roy. Soc. Med. 25: 1, 1931. MedlineGoogle Scholar21. BOWERAFFELDTWEST AGJEH: Treatment of the anginose type of infectious mononucleosis with gamma globulin. J. Pediat. 35: 58, 1949. CrossrefMedlineGoogle Scholar22. KAHLSTORF A: Zur Strahlenbehandlung der lymphoidzelligen angina. Strahlentherapie 54: 459, 1935. Google Scholar23. LEWIS PL: Infectious mononucleosis treated with chloromycetin. J. Pediat. 35: 630, 1949. CrossrefMedlineGoogle Scholar24. HIRSCH FG: Infectious mononucleosis; report of a relapsing case treated with chloromycetin. US Nav. Med. Bull. 49: 1081, 1949. MedlineGoogle Scholar25. PAYNECRENSHAW RFF: Chloromycetin in infectious mononucleosis. J. Med. Ass. Georgia 40: 75, 1951. MedlineGoogle Scholar26. RAVENNA P: Treatment of severe infectious mononucleosis with auromycin. Illinois Med. J. 98: 257, 1950. Google Scholar27. BERNREITER M: Infectious mononucleosis; treatment with sulfanilamide. J. Kansas Med. Soc. 39: 513, 1938. Google Scholar28. WALKER SH: The failure of antibiotic therapy in infectious mononucleosis. Amer. J. Med. Sci. 226: 65, 1953. CrossrefMedlineGoogle Scholar29. REDMOND AJ: Infectious mononuclosis treated with ACTH. New York J. Med. 54: 3411, 1954. MedlineGoogle Scholar30. MANDELMARILLEYGAINES WRJLM: Corticotropin in severe anginose infectious mononucleosis. JAMA 158: 1021, 1955. CrossrefMedlineGoogle Scholar31. FRENKELSHIVERBERGCARIS EPCBPTN: Meningoencephalitis in infectious mononucleosis; report of a case treated with cortisone. JAMA 162: 885, 1956. CrossrefMedlineGoogle Scholar32. FIESECHEURADDING MJSJ: Guillain-Barre syndrome in infectious mononucleosis. Arch. Intern. Med. 92: 438, 1953. CrossrefGoogle Scholar33. ERWINWEBERMANNING WRWRT: Complications of infectious mononucleosis. Amer. J. Med. Sci. 238: 699, 1959. CrossrefMedlineGoogle Scholar34. BERTINOSIMMONSDONOHUE JRBMDM: Increased activity of some folic acid enzyme systems in infectious mononucleosis. Blood 19: 587, 1962. CrossrefMedlineGoogle Scholar35. CUSTERSMITH RPEB: The pathology of infectious mononucleosis. Blood 3: 830, 1948. CrossrefMedlineGoogle Scholar36. WECHSLERROSENBLUMSILLS HFAHCT: Infectious mononucleosis: Report of an epidemic in an army post. Ann. Intern. Med. 25: 113, 1946. LinkGoogle Scholar37. TIDYDANIEL HLEC: Glandular fever and infective mononucleosis with account of an epidemic. Lancet 2: 9, 1923. CrossrefGoogle Scholar38. STEVENS JE: Infectious mononucleosis: clinical analysis of 210 sporadic cases. Virginia Med. Monthly 79: 74, 1952. MedlineGoogle Scholar39. MELVILLE HJ: Spontaneous rupture of spleen complicating infectious mononucleosis. Med. J. Aust. 1: 356, 1955. CrossrefGoogle Scholar40. LEIBOWITZBRODY SH: Cirrhosis of the liver following infectious mononucleosis. Amer. J. Med. 8: 675, 1950. CrossrefMedlineGoogle Scholar41. BICKEL G: Cirrhose atrophique du foie et mononucleose infectieuse. Bull. Soc. Med. hop. Paris 64: 923, 1948. MedlineGoogle Scholar42. HALLARCHER BDFC: Acute hemolytic anemia associated with infectious mononucleosis. New Engl. J. Med. 249: 973, 1953. CrossrefMedlineGoogle Scholar43. APPELMANGORDON DHGB: Acute hemolytic anemia complicating infectious mononucleosis: report of two cases. Ann. Intern. Med. 41: 371, 1954. LinkGoogle Scholar44. HUNTINGTON PW: Hemolytic anemia in infectious mononucleosis. Delaware Med. J. 23: 165, 1951. MedlineGoogle Scholar45. WILSONWARDGRAY SJCELW: Infectious lymphadenosis (mononucleosis) and hemolytic anemia in Negro: recovery following splenectomy. Blood 4: 189, 1949. CrossrefMedlineGoogle Scholar46. OGILVIEPARRY CMTE: Infectious mononucleosis with thrombocytopenic purpura. Brit. Med. J. 2: 977, 1952. CrossrefMedlineGoogle Scholar47. ANGLEALT RMHL: Thrombocytopenic purpura complicating infectious mononucleosis. Blood 5: 449, 1950. CrossrefMedlineGoogle Scholar48. COPEMAN HA: Infectious mononucleosis with severe thrombocytopenic purpura. Med. J. Aust. 43: 925, 1956. CrossrefMedlineGoogle Scholar48. SCHUMACHER HR: Infectious mononucleosis complicated by chronic thrombocytopenia. JAMA 177: 515, 1961. CrossrefMedlineGoogle Scholar50. MILLERURICCHIOPHILLIPS HJFRW: Acute pericarditis associated with infectious mononucleosis. New Engl. J. Med. 249: 136, 1953. CrossrefMedlineGoogle Scholar51. ROSEMANBARRY DMRM: Acute pericarditis as the first manifestation of infectious mononucleosis. Ann. Intern. Med. 47: 351, 1957. LinkGoogle Scholar52. WEBSTER BH: Cardiac complications of infectious mononucleosis. Review of literature and report of five cases. Amer. J. Med. Sci. 234: 62, 1957. CrossrefMedlineGoogle Scholar53. SHUGOLL GI: Pericarditis associated with infectious mononucleosis. Arch. Intern. Med. 100: 630, 1957. CrossrefGoogle Scholar54. FISHBARTON MHR: Heart involvement in infectious mononucleosis. Arch. Intern. Med. 101: 636, 1958. CrossrefGoogle Scholar55. TANNER OR: Ocular manifestation of infectious mononucleosis. Arch. Ophthal. 51: 229, 1954. CrossrefMedlineGoogle Scholar56. BLAUSTEINCACCAVO AUA: Infectious mononucleosis complicated by bilateral pailloretinal edema. Arch. Ophthal. 43: 853, 1950. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: HAROLD R. SCHUMACHER; WILLIAM A. JACOBSON; CARL R. BEMILLER, M.D.Affiliations: USN Portsmouth, VirginiaFrom the Department of Medicine, United States Naval Hospital, Portsmouth, Virginia.The opinions or assertions contained herein are those of the authors and are not to be construed as official or reflecting the views of the Navy Department or of the Naval Service at large.Requests for reprints should be addressed to H. R. Schumacher, M.D., Jefferson Medical College Hospital, Philadelphia 7, Pennsylvania. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited bySafety of Short-Term Treatments with Oral Chloroquine and Hydroxychloroquine in Patients with and without COVID-19: A Systematic ReviewEffects of chloroquine or hydroxychloroquine treatment on non‐SARS‐CoV2 viral infections: A systematic review of clinical studiesSteroids for symptom control in infectious mononucleosisEpstein-Barr Virus (Infectious Mononucleosis, Epstein-Barr Virus–Associated Malignant Diseases, and Other Diseases)Cochrane Review: Steroids for symptom control in infectious mononucleosisCommentary on 'Steroids for symptom control in infectious mononucleosis (Review)' with a response from the review authorsEpstein-Barr Virus (Infectious Mononucleosis, Epstein-Barr Virus–Associated Malignant Diseases, and Other Diseases)Steroids for symptom control in infectious mononucleosisInfectious mononucleosis and bilateral peritonsillar abscesses resulting in airway obstructionBenign lymphoproliferative disordersAcute tonsillectomy in the management of infectious mononucleosisSteroids for airway problems in glandular feverOtolaryngological complications in infectious mononucleosisInfectious mononucleosis in the athletePeritonsillar abscess: A complication of corticosteroid treatment in infectious mononucleosisHow Frequent Is Bacterial Superinfection of the Pharynx in Infectious Mononucleosis?Die infektiöse MononucleoseRespiratory obstruction in glandular feverMononucleosis infectiosa (Pfeiffer'sches Drüsenfieber)Mononucleosis infectiosa (Pfeiffer'sches Drüsenfieber) 1 February 1963Volume 58, Issue 2Page: 217-228KeywordsAntibioticsDrugsEdemaHospital medicineSigns and symptomsSteroids ePublished: 1 December 2008 Issue Published: 1 February 1963 PDF downloadLoading ...

https://doi.org/10.7326/0003-4819-58-2-217
American Journal of Clinical Pathology · 1953 · 17 citations

Infectious Mononucleosis

AbstractJournal Article Infectious Mononucleosis Get access Infectious Mononucleosis. By Liebowitz Sidney, M.D., Associate Physician, Beth Israel Hospital, New York. 163 pp., 3 figs., 15 tables. $4.75. New York Grune & Stratton, Inc., 1953. Frank J. Heck Frank J. Heck Rochester, Minnesota Search for other works by this author on: Oxford Academic Google Scholar American Journal of Clinical Pathology, Volume 23, Issue 8, 1 August 1953, Pages 803–804, https://doi.org/10.1093/ajcp/23.8.803a Published: 01 August 1953

https://doi.org/10.1093/ajcp/23.8.803a
Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics) · 2016 · 3 citations · open access

Mononucleosis-like syndrome in children

AbstractThe paper gives the results of following up 88 children aged 8.5 months to 17 years who were treated at the Republican Clinical Infectious Diseases Hospital in Kazan in 2015–2016 for a diagnosis of infectious mononucleosis. It considers its clinical manifestations in relation to the etiology of the disease and hospitalization outcomes. Main laboratory changes are assessed.

https://doi.org/10.21508/1027-4065-2016-61-5-132-135
Postgraduate Medicine · 1968 · 2 citations

Systemic Effects of Mononucleosis

AbstractInfectious mononucleosis is rarely severe enough to cause serious trouble. But when it does, it may produce grave, even fatal complications. Generally physicians cannot prevent these complications. They can, however, treat some patients with steroids and support others with general measures.

https://doi.org/10.1080/00325481.1968.11693254
Hospital Medicine · 2001 · 1 citations

Infectious mononucleosis: not always what it seems

AbstractInfectious mononucleosis (IM) is a benign disease of healthy young people. Patients and their relatives therefore expect a speedy and complete recovery. This editorial explores some of the unexpected diagnostic and management problems encountered in this otherwise commonplace illness.

https://doi.org/10.12968/hosp.2001.62.7.1604

Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.

DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.